Aomni raises $4M to help sales teams close more deals with AI-powered research agents that provide real-time, deep prospect intelligence—boosting close rates by up to 40%.

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate FDMT stock a Buy.

It might be a bit of a head-scratcher at first, but yes, AMD's Ryzen 7 7800X3D was recently available for $99 at one retail ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.

Asus ROG Flow Z13 is a hybrid device that never quite feels at home amongst either laptops or tablets. It’s still one of the ...

In addition to AVT06, which is a biosimilar candidate for Eylea® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea® HD (aflibercept) 8 mg. Teva also ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Age-related macular degeneration (AMD) is a progressive eye condition that primarily affects people over the age of 50. AMD is a leading cause of vision loss in people over 50.

Intel's rivals Taiwan Semiconductor and Broadcom are eyeing deals that would break the U.S. chipmaker in two, the Wall Street ...

The first of Opthea’s (ASX:OPT) two phase III eye disease trials has hit a key development milestone, with the last patient ...

Broadcom has been closely examining Intel's chip design and marketing business, the Journal reported, adding that the company ...